BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 2419425)

  • 1. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
    Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
    J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
    Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
    Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
    Medof ME; Nussenzweig V
    J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement receptor is an inhibitor of the complement cascade.
    Iida K; Nussenzweig V
    J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
    J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
    Pangburn MK
    Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells.
    Kinoshita T; Medof ME; Hong K; Nussenzweig V
    J Exp Med; 1986 Nov; 164(5):1377-88. PubMed ID: 2430040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
    Kinoshita T; Medof ME; Nussenzweig V
    J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
    Rawal N; Rajagopalan R; Salvi VP
    J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.
    Kuttner-Kondo LA; Dybvig MP; Mitchell LM; Muqim N; Atkinson JP; Medof ME; Hourcade DE
    J Biol Chem; 2003 Dec; 278(52):52386-91. PubMed ID: 14561755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.